CA2737496A1 - Conjugues d'antifolates liant le recepteur de folate - Google Patents
Conjugues d'antifolates liant le recepteur de folate Download PDFInfo
- Publication number
- CA2737496A1 CA2737496A1 CA2737496A CA2737496A CA2737496A1 CA 2737496 A1 CA2737496 A1 CA 2737496A1 CA 2737496 A CA2737496 A CA 2737496A CA 2737496 A CA2737496 A CA 2737496A CA 2737496 A1 CA2737496 A1 CA 2737496A1
- Authority
- CA
- Canada
- Prior art keywords
- conjugate
- antifolate
- linker
- acid
- folate receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9765508P | 2008-09-17 | 2008-09-17 | |
US61/097,655 | 2008-09-17 | ||
PCT/US2009/057363 WO2010033733A1 (fr) | 2008-09-17 | 2009-09-17 | Conjugués d'antifolates liant le récepteur de folate |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2737496A1 true CA2737496A1 (fr) | 2010-03-25 |
Family
ID=42039876
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2737496A Abandoned CA2737496A1 (fr) | 2008-09-17 | 2009-09-17 | Conjugues d'antifolates liant le recepteur de folate |
Country Status (9)
Country | Link |
---|---|
US (5) | US8546425B2 (fr) |
EP (1) | EP2349274A4 (fr) |
JP (1) | JP5675619B2 (fr) |
CN (1) | CN102215844A (fr) |
AU (1) | AU2009293140A1 (fr) |
CA (1) | CA2737496A1 (fr) |
IL (1) | IL211763A (fr) |
NZ (1) | NZ592255A (fr) |
WO (1) | WO2010033733A1 (fr) |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2529758A3 (fr) * | 2003-01-27 | 2013-01-02 | Endocyte, Inc. | Conjugués d'administration de médicaments à liaison au récepteur de vitamines |
WO2006012527A1 (fr) | 2004-07-23 | 2006-02-02 | Endocyte, Inc. | Groupes de liaison bivalents et conjugués de ceux-ci |
CA2680535C (fr) | 2007-03-14 | 2016-09-20 | Endocyte, Inc. | Conjugues d'administration de medicament lies a un ligand de liaison de tubulysines |
US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
WO2009002993A1 (fr) | 2007-06-25 | 2008-12-31 | Endocyte, Inc. | Conjugués contenant des lieurs espaceurs hydrophiles |
US9901567B2 (en) | 2007-08-01 | 2018-02-27 | Syntarga B.V. | Substituted CC-1065 analogs and their conjugates |
PL2187965T3 (pl) | 2007-08-17 | 2020-05-18 | Purdue Research Foundation | Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania |
HUE035798T2 (en) | 2008-11-03 | 2018-05-28 | Syntarga Bv | CC-1065 analogues and conjugates |
AU2011206133B2 (en) * | 2010-01-12 | 2014-09-18 | Pola Chemical Industries Inc. | Prophylactic or ameliorating agent for pigmentation |
CN103037900B (zh) | 2010-02-24 | 2016-04-06 | 伊缪诺金公司 | 叶酸受体1抗体与免疫缀合物以及其用途 |
US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
HUE030846T2 (en) | 2010-04-21 | 2017-06-28 | Syntarga Bv | Conjugates of CC-1065 analogues and bifunctional linkers |
CA2812543A1 (fr) * | 2010-09-27 | 2012-04-12 | Endocyte, Inc. | Conjugues de l'acide folique destines a traiter une inflammation de l'oeil |
CA2817219A1 (fr) * | 2010-11-12 | 2012-05-18 | Endocyte, Inc. | Procedes de traitement du cancer |
EP2694106B1 (fr) | 2011-04-01 | 2017-12-13 | ImmunoGen, Inc. | Procédé pour augmenter l'efficacité d'une cancérothérapie ciblant folr1 |
EP3228325A1 (fr) | 2011-06-10 | 2017-10-11 | Mersana Therapeutics, Inc. | Conjugués protéine-polymère-médicament |
WO2013126797A1 (fr) | 2012-02-24 | 2013-08-29 | Purdue Research Foundation | Ciblage du récepteur de la cholécystokinine de type b pour imagerie et thérapie |
US9629918B2 (en) | 2012-02-29 | 2017-04-25 | Purdue Research Foundation | Folate receptor alpha binding ligands |
US20140080175A1 (en) | 2012-03-29 | 2014-03-20 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
US20140079636A1 (en) * | 2012-04-16 | 2014-03-20 | Dinesh U. Chimmanamada | Targeted therapeutics |
EP2849790B1 (fr) * | 2012-05-15 | 2019-04-10 | Concortis Biosystems, Corp | Conjugués de médicament, procédés de conjugaison, et utilisations associées |
CA2878733C (fr) | 2012-07-12 | 2021-09-14 | Hangzhou Dac Biotech Co., Ltd | Conjugues de molecule de liaison cellulaire et d'agents cytotoxiques |
RU2668824C2 (ru) | 2012-08-31 | 2018-10-02 | Иммьюноджен Инк. | Диагностические анализы и наборы для детекции фолатного рецептора 1 |
EP2708243A1 (fr) | 2012-09-17 | 2014-03-19 | OntoChem GmbH | Molécules cytotoxiques liés à un ligand de récepteur |
WO2014062697A2 (fr) | 2012-10-16 | 2014-04-24 | Endocyte, Inc. | Conjugués d'administration de médicament contenant des acides aminés artificiels et procédés d'utilisation |
KR102499944B1 (ko) | 2012-11-15 | 2023-02-14 | 엔도사이트, 인코포레이티드 | Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트 |
AU2012395148B2 (en) | 2012-11-24 | 2016-10-27 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules |
CA2892863C (fr) | 2012-12-10 | 2022-03-15 | Mersana Therapeutics, Inc. | Echafaudage polymere fonde sur des filaments helicoidaux apparies (phf) pour l'administration ciblee de medicaments |
WO2014093640A1 (fr) | 2012-12-12 | 2014-06-19 | Mersana Therapeutics,Inc. | Conjugués hydroxy-polymère-médicament-protéine |
EP2934532B1 (fr) * | 2012-12-20 | 2019-10-23 | Purdue Research Foundation | Cellules t exprimant un récepteur d'antigène chimérique et produits thérapeutiques anticancéreux |
EP2968335B1 (fr) | 2013-03-15 | 2019-03-27 | Purdue Research Foundation | Synthèse et composition de groupes de liaison d'acides aminés conjugués à des composés utilisés pour l'imagerie ciblée de tumeurs |
BR112016003665B1 (pt) | 2013-08-30 | 2024-01-09 | Immunogen, Inc | Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga especificamente a um epítopo do receptor de folato 1, polinucleotídeo, vetor,célula hospedeira procariótica ou de levedura, composição, seus usos e métodos in vitro para detecção da expressão do receptor de folato 1 e identificação de um câncer |
AU2014318826B2 (en) | 2013-09-10 | 2019-10-10 | Madrigal Pharmaceuticals, Inc. | Targeted therapeutics |
EP4374924A2 (fr) | 2013-10-18 | 2024-05-29 | Novartis AG | Inhibiteurs marqués de l'antigène membranaire spécifique de la prostate (psma), leur utilisation comme agents d'imagerie et agents pharmaceutiques pour le traitement du cancer de la prostate |
WO2015066053A2 (fr) | 2013-10-28 | 2015-05-07 | Synta Pharmaceuticals Corp. | Thérapies ciblées |
US20170168074A1 (en) | 2013-11-25 | 2017-06-15 | Ontochem Gmbh | Method for diagnosing G-protein coupled receptor-related diseases |
CA2935430C (fr) | 2014-01-10 | 2018-09-18 | Synthon Biopharmaceuticals B.V. | Conjugues anticorps-medicaments a base de duocarmycine utilisables dans le cadre du traitement du cancer de l'endometre |
CA2935433C (fr) | 2014-01-10 | 2019-04-02 | Synthon Biopharmaceuticals B.V. | Conjugues anticorps-medicament anti-her2 de duocarmycine ayant une activite contre les neoplasmes malins exprimant her2 |
AU2015205574B2 (en) | 2014-01-10 | 2019-08-15 | Byondis B.V. | Method for purifying Cys-linked antibody-drug conjugates |
JP2017505777A (ja) | 2014-01-29 | 2017-02-23 | シンタ ファーマスーティカルズ コーポレーション | 標的化治療薬 |
ES2960619T3 (es) | 2014-02-28 | 2024-03-05 | Hangzhou Dac Biotech Co Ltd | Enlazadores cargados y sus usos para la conjugación |
AU2015224576A1 (en) | 2014-03-03 | 2016-09-22 | Madrigal Pharmaceuticals, Inc. | Targeted therapeutics |
WO2015135659A1 (fr) | 2014-03-14 | 2015-09-17 | Ontochem Gmbh | Ligand-récepteur lié à des molécules cytotoxiques |
EP3131586A4 (fr) | 2014-03-18 | 2017-10-25 | Madrigal Pharmaceuticals, Inc. | Agents thérapeutiques cibles |
US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
US9481678B2 (en) * | 2015-02-09 | 2016-11-01 | Duquesne University Of The Holy Ghost | Substituted pyrrolo[2,3-D]dipyrimidines for selectively targeting tumor cells with FR-alpha and FR-beta type receptors |
CN107847609A (zh) | 2015-03-13 | 2018-03-27 | 恩多塞特公司 | 用于治疗疾病的缀合物 |
US20180110871A1 (en) * | 2015-04-17 | 2018-04-26 | Endocyte, Inc. | Dual disulfide drug conjugates |
WO2016179011A1 (fr) * | 2015-05-01 | 2016-11-10 | Endocyte, Inc. | Conjugués d'antifolates pour le traitement de l'inflammation |
WO2016183131A1 (fr) | 2015-05-11 | 2016-11-17 | Purdue Research Foundation | Conjugués ligand-ionophore |
NZ739830A (en) | 2015-07-12 | 2021-12-24 | Hangzhou Dac Biotech Co Ltd | Bridge linkers for conjugation of cell-binding molecules |
US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
US10172875B2 (en) | 2015-09-17 | 2019-01-08 | Immunogen, Inc. | Therapeutic combinations comprising anti-FOLR1 immunoconjugates |
MX2018006218A (es) | 2015-12-04 | 2018-09-05 | Seattle Genetics Inc | Conjugados de compuestos de tubulisina cuaternizada. |
US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
WO2018182776A1 (fr) * | 2016-03-29 | 2018-10-04 | Endocyte, Inc. | Conjugué de folate destiné à être utilisé dans le ciblage de macrophages associés à une tumeur |
WO2017205447A1 (fr) * | 2016-05-24 | 2017-11-30 | Endocyte, Inc. | Méthodes de traitement du cancer avec un composé ligand de psma-tubulysine |
US20180036312A1 (en) * | 2016-08-02 | 2018-02-08 | ISI Life Sciences Inc. | Novel Scaffolds for Intracellular Compound Delivery for the Detection of Cancer Cells |
US10239891B2 (en) * | 2017-05-15 | 2019-03-26 | Indicator Systems International, Inc. | Compositions to detect remnant cancer cells |
WO2018026965A1 (fr) | 2016-08-02 | 2018-02-08 | Isi Life Sciences, Inc. | Méthode de détection de cellules cancéreuses. |
US20210308277A1 (en) | 2016-11-14 | 2021-10-07 | Hangzhou Dac Biotech Co., Ltd. | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers |
CN110612119A (zh) | 2017-02-07 | 2019-12-24 | 西雅图儿童医院(Dba西雅图儿童研究所) | 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂 |
JP7178355B2 (ja) | 2017-02-28 | 2022-11-25 | エンドサイト・インコーポレイテッド | Car t細胞療法のための組成物および方法 |
US10753942B2 (en) | 2017-05-15 | 2020-08-25 | Indicator Systems International, Inc. | Methods to detect remnant cancer cells |
JP2020524156A (ja) | 2017-06-20 | 2020-08-13 | マドリガル ファーマシューティカルズ インコーポレイテッドMadrigal Pharmaceuticals,Inc. | 標的治療薬を含む併用療法 |
KR20200016875A (ko) | 2017-06-20 | 2020-02-17 | 마드리갈 파마슈티칼스 인코포레이티드 | 표적화 치료제 |
JP2021512147A (ja) | 2018-01-22 | 2021-05-13 | エンドサイト・インコーポレイテッドEndocyte, Inc. | Car t細胞の使用方法 |
JP2022513299A (ja) | 2018-12-19 | 2022-02-07 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | リソソーム標的化のための二官能性分子ならびに関連する組成物および方法 |
KR20220029725A (ko) | 2019-06-29 | 2022-03-08 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | 세포-결합 분자-튜불리신 유도체 접합체 및 이의 제조 방법 |
EP4275758A3 (fr) | 2020-10-27 | 2024-02-21 | Elucida Oncology, Inc. | Procédés de fonctionnalisation de nanoparticules |
WO2022136234A1 (fr) * | 2020-12-22 | 2022-06-30 | F. Hoffmann-La Roche Ag | Procédé de détection d'un analyte d'intérêt dans un échantillon |
US20230158154A1 (en) * | 2021-11-09 | 2023-05-25 | Tubulis Gmbh | Conjugates comprising a phosphorus (v) and a camptothecin moiety |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4024A (en) * | 1845-05-01 | Cutting and crushing corn-fodder | ||
US4713249A (en) | 1981-11-12 | 1987-12-15 | Schroeder Ulf | Crystallized carbohydrate matrix for biologically active substances, a process of preparing said matrix, and the use thereof |
US5266333A (en) | 1985-03-06 | 1993-11-30 | American Cyanamid Company | Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration of growth hormone |
ZA861235B (en) * | 1985-03-08 | 1986-10-29 | Univ Princeton | Pyrido(2,3-d)pyrimidine derivatives |
US5417982A (en) | 1994-02-17 | 1995-05-23 | Modi; Pankaj | Controlled release of drugs or hormones in biodegradable polymer microspheres |
US5547668A (en) | 1995-05-05 | 1996-08-20 | The Board Of Trustees Of The University Of Illinois | Conjugates of folate anti-effector cell antibodies |
AUPQ014799A0 (en) * | 1999-05-04 | 1999-05-27 | Access Pharmaceuticals Australia Pty Limited | Amplification of folate-mediated targeting to tumor cells using polymers |
DE60231868D1 (de) * | 2001-04-24 | 2009-05-20 | Purdue Research Foundation | Folat-mimetika und deren folatrezeptorbindende konjugate |
EP2529758A3 (fr) | 2003-01-27 | 2013-01-02 | Endocyte, Inc. | Conjugués d'administration de médicaments à liaison au récepteur de vitamines |
FR2856689A1 (fr) * | 2003-06-25 | 2004-12-31 | Guerbet Sa | Composes specifiques a forte relaxivite |
US7290958B2 (en) | 2004-12-03 | 2007-11-06 | Airfield Systems, Llc | Subsurface drainage system and drain structure therefor |
US8044200B2 (en) | 2005-03-16 | 2011-10-25 | Endocyte, Inc. | Synthesis and purification of pteroic acid and conjugates thereof |
CN103893779A (zh) | 2005-08-19 | 2014-07-02 | 恩多塞特公司 | 多药物配体缀合物 |
EP2382995A3 (fr) * | 2005-08-19 | 2013-09-25 | Endocyte, Inc. | Conjugués de ligands d'alcaloïdes de Vinca, analogues et dérivés |
EP1917027A2 (fr) | 2005-08-24 | 2008-05-07 | Protherics Medicines Development Limited | Clivage de composes antifoliques |
WO2009002993A1 (fr) | 2007-06-25 | 2008-12-31 | Endocyte, Inc. | Conjugués contenant des lieurs espaceurs hydrophiles |
-
2009
- 2009-09-17 NZ NZ592255A patent/NZ592255A/xx not_active IP Right Cessation
- 2009-09-17 AU AU2009293140A patent/AU2009293140A1/en not_active Abandoned
- 2009-09-17 JP JP2011527074A patent/JP5675619B2/ja active Active
- 2009-09-17 EP EP09815218.4A patent/EP2349274A4/fr active Pending
- 2009-09-17 WO PCT/US2009/057363 patent/WO2010033733A1/fr active Application Filing
- 2009-09-17 US US13/063,889 patent/US8546425B2/en active Active - Reinstated
- 2009-09-17 CN CN2009801425326A patent/CN102215844A/zh active Pending
- 2009-09-17 CA CA2737496A patent/CA2737496A1/fr not_active Abandoned
-
2011
- 2011-03-16 IL IL211763A patent/IL211763A/en not_active IP Right Cessation
-
2013
- 2013-08-26 US US14/010,122 patent/US9192682B2/en active Active
-
2015
- 2015-10-21 US US14/919,518 patent/US9549992B2/en active Active
-
2016
- 2016-12-13 US US15/377,844 patent/US10363250B2/en active Active
-
2019
- 2019-06-13 US US16/440,882 patent/US11219622B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US9549992B2 (en) | 2017-01-24 |
EP2349274A1 (fr) | 2011-08-03 |
US20140213760A1 (en) | 2014-07-31 |
JP5675619B2 (ja) | 2015-02-25 |
EP2349274A4 (fr) | 2014-12-17 |
WO2010033733A1 (fr) | 2010-03-25 |
US20110172254A1 (en) | 2011-07-14 |
US20170246314A1 (en) | 2017-08-31 |
WO2010033733A4 (fr) | 2010-05-06 |
CN102215844A (zh) | 2011-10-12 |
IL211763A0 (en) | 2011-06-30 |
JP2012502921A (ja) | 2012-02-02 |
US8546425B2 (en) | 2013-10-01 |
US9192682B2 (en) | 2015-11-24 |
IL211763A (en) | 2014-07-31 |
US20200147072A1 (en) | 2020-05-14 |
US11219622B2 (en) | 2022-01-11 |
NZ592255A (en) | 2013-07-26 |
US20160263237A1 (en) | 2016-09-15 |
AU2009293140A1 (en) | 2010-03-25 |
US10363250B2 (en) | 2019-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11219622B2 (en) | Folate receptor binding conjugates of antifolates | |
US10738086B2 (en) | Conjugates containing hydrophilic spacer linkers | |
US20170327537A1 (en) | Binding ligand linked drug delivery conjugates of tubulysins | |
AU2004210136B2 (en) | Vitamin receptor binding drug delivery conjugates | |
US20130116195A1 (en) | Binding ligand linked drug delivery conjugates of tubulysins | |
EP2374480A2 (fr) | Conjugués de ligands multi-médicaments | |
US10500204B2 (en) | Vitamin receptor drug delivery conjugates for treating inflammation | |
US20130203680A1 (en) | Folate conjugates for treating inflammation of the eye | |
AU2013203147A1 (en) | Binding ligand linked drug delivery conjugates of tubulysins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20140731 |
|
FZDE | Discontinued |
Effective date: 20161031 |